Pro-neurogenic compounds
This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protection from neuron cell death.
1. A method for treating major depression comprising: administering to a subject in need thereof an effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the following formula:
wherein:
R 3 and R 6 are each independently selected from halo, C 1 -C 6 alkyl, C 2 -C 6 alkynyl, cyclopropyl, —N 3 , and cyano;
A is CR A1 R A2 , wherein R A1 is selected from hydrogen, halo, C 1 -C 3 alkyl, and OR 9 , and R A2 is selected from halo, C 1 -C 3 alkyl, and OR 9 ;
Z is selected from —NHR 10 ; —N(CH 3 )R 11 ; —OR 12 ; and —S(O) n R 13 , wherein n is 0, 1, or 2;
R 9 is hydrogen or C 1 -C 3 alkyl that is optionally substituted with hydroxyl or C 1 -C 3 alkoxy;
R 10 , R 11 , R 12 and R 13 are each independently selected from:
(a) C 6 -C 10 aryl that is optionally substituted with 1 to 4 R b ; or
(b) heteroaryl containing from 6-14 ring atoms, wherein from 1-6 of the ring atoms are independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1 to 4 R b ;
R b at each occurrence is independently selected from the substituents delineated in (aa) through (dd) below:
(aa) C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; —O—(CH 2 ) 1-3 —-[O(CH 2 ) 1-3 ] 1-3 —H; C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl);
(bb) halo; hydroxyl; cyano; nitro; —NH 2 ; azido; sulfhydryl; C 2 -C 6 alkenyl; C 2 -C 6 alkynyl; —C(O)H; —C(O)(C 1 -C 6 alkyl); —C(O)(C 1 -C 6 haloalkyl); C(O)OH; —C(O)O(C 1 -C 6 alkyl); —C(O)NH 2 ; —C(O)NH(C 1 -C 6 alkyl); C(O)N(C 1 -C 6 alkyl) 2 ; —SO 2 (C 1 -C 6 alkyl); —SO 2 NH 2 ; —SO 2 NH(C 1 -C 6 alkyl); —SO 2 N(C 1 -C 6 alkyl) 2 ;
(cc) C 3 -C 6 cycloalkyl or heterocyclyl containing from 5 to 6 ring atoms, wherein from 1 to 2 of the ring atoms of the heterocyclyl is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and
(dd) phenyl or heteroaryl containing from 5 to 6 ring atoms, wherein from 1 to 2 of the ring atoms of the heteroaryl is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S;
wherein each of said phenyl and heteroaryl is optionally substituted with from 1 to 3 substituents independently selected from halo; hydroxyl; cyano; nitro; —NH 2 ; —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl;
wherein when R 3 and R 6 are both halo, one of R A1 and R A2 is OH and the other is hydrogen, Z is —NHR 10 , and R 10 is C 6 -C 10 aryl that is optionally substituted with 1 to 4 R b , then R 10 is unsubstituted phenyl or phenyl substituted with 1 R b .
2. The method of claim 1 , wherein the carbon attached to R A1 and R A2 is substituted with four different substituents, and is (R) or (S) configured.
3. The method of claim 2 , wherein the compound or salt is (+) (dextrorotatory) or (−) (levororotatory).
4. The method of claim 1 , wherein the effective amount of the compound or salt reduces neuron cell death.
5. The method of claim 1 , wherein the compound is N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-3-methoxyaniline.
6. A method for treating major depression comprising: administering to a subject in need thereof an effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the following formula:
wherein
R 3 and R 6 are each independently selected from halo, CH 3 , ethynyl, cyclopropyl, —N 3 , and cyano;
R A1 and R A2 are each independently selected from hydrogen, halo, CH 3 , and OR 9 , wherein one of R A1 and R A2 is halo or OR 9 ;
Z is selected from —NHR 10 ; —N(CH 3 )R 11 ; —OR 12 ; and —S(O)—R 13 , wherein n is 0, 1, or 2;
R 9 is hydrogen or C 1 -C 3 alkyl that is optionally substituted with hydroxyl or C 1 -C 3 alkoxy;
R 10 , R 11 , R 12 and R 13 are each independently selected from:
(a) C 6 -C 10 aryl that is optionally substituted with 1 to 4 R b ; or
(b) heteroaryl containing from 6-14 ring atoms, wherein from 1-6 of the ring atoms are independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1 to 4 R b ;
R b at each occurrence is independently selected from the substituents delineated in (aa) through (dd) below:
(aa) C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; —O—(CH 2 ) 1-3 -[O(CH 2 ) 1-3 ] 1-3 —H; C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl);
(bb) halo; hydroxyl; cyano; nitro; —NH 2 ; azido; sulfhydryl; C 2 -C 6 alkenyl; C 2 -C 6 alkynyl; —C(O)H; —C(O)(C 1 -C 6 alkyl); —C(O)(C 1 -C 6 haloalkyl); C(O)OH; —C(O)O(C 1 -C 6 alkyl); —C(O)NH 2 ; —C(O)NH(C 1 -C 6 alkyl); C(O)N(C 1 -C 6 alkyl) 2 ; —SO 2 (C 1 -C 6 alkyl); —SO 2 NH 2 ; —SO 2 NH(C 1 -C 6 alkyl); —SO 2 N(C 1 -C 6 alkyl) 2 ;
(cc) C 3 -C 6 cycloalkyl or heterocyclyl containing from 5 to 6 ring atoms, wherein from 1 to 2 of the ring atoms of the heterocyclyl is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and
(dd) phenyl or heteroaryl containing from 5 to 6 ring atoms, wherein from 1 to 2 of the ring atoms of the heteroaryl is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S;
wherein each of said phenyl and heteroaryl is optionally substituted with from 1 to 3 substituents independently selected from halo; hydroxyl; cyano; nitro; —NH 2 ; —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl;
wherein when R 3 and R 6 are both halo, one of R A1 and R A2 is OH and the other is hydrogen, Z is —NHR 10 , and R 10 is C 6 -C 10 aryl that is optionally substituted with 1 to 4 R b , then R 10 is unsubstituted phenyl or phenyl substituted with 1 R b .
7. The method of claim 6 , wherein the carbon attached to R A1 and R A2 is substituted with four different substituents, and is (R) or (S) configured.
8. The method of claim 6 , wherein the effective amount of the compound or salt reduces neuron cell death.
9. A method for treating major depression comprising: administering to a subject in need thereof an effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the following formula:
wherein:
Z is selected from —NHR 10 ; —N(CH 3 )R 11 ; —OR 12 ; and —S(O) n R 13 , wherein n is 0, 1, or 2;
R 10 , R 11 , R 12 and R 13 are each independently selected from:
(a) C 6 -C 10 aryl that is optionally substituted with 1 to 4 R b ; or
(b) heteroaryl containing from 6-14 ring atoms, wherein from 1-6 of the ring atoms are independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1 to 4 R b ;
R b at each occurrence is independently selected from the substituents delineated in (aa) through (dd) below:
(aa) C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; —O—(CH 2 ) 1-3 -[O(CH 2 ) 1-3 ] 1-3 —H; C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl);
(bb) halo; hydroxyl; cyano; nitro; —NH 2 ; azido; sulfhydryl; C 2 -C 6 alkenyl; C 2 -C 6 alkynyl; —C(O)H; —C(O)(C 1 -C 6 alkyl); —C(O)(C 1 -C 6 haloalkyl); C(O)OH; —C(O)O(C 1 -C 6 alkyl); —C(O)NH 2 ; —C(O)NH(C 1 -C 6 alkyl); C(O)N(C 1 -C 6 alkyl) 2 ; —SO 2 (C 1 -C 6 alkyl); —SO 2 NH 2 ; —SO 2 NH(C 1 -C 6 alkyl); —SO 2 N(C 1 -C 6 alkyl) 2 ;
(cc) C 3 -C 6 cycloalkyl or heterocyclyl containing from 5 to 6 ring atoms, wherein from 1 to 2 of the ring atoms of the heterocyclyl is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and
(dd) phenyl or heteroaryl containing from 5 to 6 ring atoms, wherein from 1 to 2 of the ring atoms of the heteroaryl is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S;
wherein each of said phenyl and heteroaryl is optionally substituted with from 1 to 3 substituents independently selected from halo; hydroxyl; cyano; nitro; —NH 2 ; —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)(C 1 -C 6 alkyl), C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl.
10. The method of claim 9 , wherein the carbon attached to fluoro is (R) or (S) configured.
11. The method of claim 10 , wherein the compound or salt is (+) (dextrorotatory) or (−) (levororotatory).
12. The method of claim 9 , wherein the effective amount of the compound or salt reduces neuron cell death.
13. The method of claim 1 , wherein R 3 and R 6 are both halo.
14. The method of claim 1 , wherein R 3 and R 6 are both bromo.
15. The method of claim 1 , wherein R A1 is selected from hydrogen, and R A2 is halo.
16. The method of claim 15 , wherein R A2 is fluoro.
17. The method of claim 1 , wherein Z is —NHR 10 .
18. The method of claim 17 , wherein R 10 is heteroaryl containing 6 ring atoms, wherein 1 of the ring atoms is N, and wherein said heteroaryl is optionally substituted with 1 R b .